Investor Presentation
Released
Released
Announcement PDF
ASX:TTX
#anchoredbyscience
Disclaimer
>
IMPORTANT INFORMATION & DISCLAIMER
USE OF THIS DOCUMENT
You must read the following notices before reading or making any use of this document or any information contained in this document. By continuing to read, use or otherwise act on this document, you agree to be bound by the following terms and conditions, including any
modifications to them, and make or give the acknowledgements, representations or warranties (as applicable). This presentation is provided for information purposes only. The information in this presentation is in a summary form, does not purport to be complete and is not
intended to be relied upon as advice to investors or other persons. The information contained in this presentation was prepared by Tetratherix Pty Limited ACN 607 771 077 (Tetratherix) as of its date, and remains subject to change without notice. This presentation has been
provided to you solely for the purpose of giving you background information about Tetratherix.
NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES
This document is not to be distributed or released in the United States.
DISTRIBUTION OUTSIDE AUSTRALIA
The distribution of this presentation to persons or in jurisdictions outside Australia may be restricted by law and any person into whose possession this document comes should seek advice on and observe those restrictions. Any failure to comply with such restrictions may
violate applicable securities law.
FORWARD-LOOKING STATEMENTS
This presentation may include forward looking statements. Such statements can generally be identified by the use of words such as 'may', 'will', 'expect', 'intend’, 'plan', 'estimate', 'anticipate', 'believe', 'continue', 'objectives', 'outlook', 'guidance‘, ‘forecast’ and similar
expressions. Indications of plans, strategies, management objectives, revenue and financial performance are also forward-looking statements. Such statements are not guarantees of future performance, and involve known and unknown risks, uncertainties, significant items
of subjective judgement, assumptions (including in relation to future events that may or may not eventuate), contingencies and other factors, many of which are outside the control of Tetratherix. No independent third party has reviewed the reasonableness of any such
statements or assumptions. No representation is made or will be made that any forward-looking statements will be achieved or will prove to be correct. Actual results, performance, operations or achievements may vary materially from any forward-looking statements.
Circumstances may change and the contents of this presentation may become outdated as a result. Readers are cautioned not to place undue reliance on forward looking statements. Except as required by law, Tetratherix assumes no obligation to release updates or
revisions to forward looking statements to reflect any changes. You should form your own views as to these matters and any assumptions on which such statements are based and not place reliance on such statements. No representation or warranty, expressed or implied,
is made as to the accuracy, reliability, adequacy or completeness of the information contained in this presentation. To the maximum extent permitted by law, Tetratherix excludes and disclaims all liability, including (without limitation) any liability for fraud or negligence, for any
expenses, losses, damages or costs incurred either as a result of the information in this presentation being inaccurate or incomplete in any way for any reason, or otherwise arising in connection with this presentation.
PAST PERFORMANCE AND RISKS
Past performance information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance. An investment in Tetratherix is subject to known and unknown risks, some of which are beyond the
control of Tetratherix, including factors and risks specific to the industry in which it operates as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets. Tetratherix does not guarantee any particular rate of
return on its performance nor does it guarantee any particular tax treatment. Prospective investors should make their own enquiries and investigations regarding all information in this presentation, including the assumptions, uncertainties and contingencies which may affect
future operations and the impact that different future outcomes may have on Tetratherix.
NO OFFER, INVITATION OR ADVICE
This presentation is not, and is not intended to constitute, financial advice, or an offer or an invitation, solicitation or recommendation to acquire or sell Tetratherix shares or any other financial products in any jurisdiction and is not a prospectus, product disclosure statement,
disclosure document or other offering document under Australian law or any other law. This presentation does not form the basis of any contract or commitment to sell or apply for securities in Tetratherix or any of its subsidiaries. It is for information purposes only. Tetratherix
does not warrant or represent that the information in this presentation is free from errors, omissions or misrepresentations or is suitable for your intended use. The information contained in this presentation has been prepared without taking account of any person’s
investment objectives, financial situation or particular needs and nothing contained in this presentation constitutes investment, legal, tax or other advice. The information provided in this presentation may not be suitable for your specific needs and should not be relied upon by
you in substitution of you obtaining independent advice. Subject to any terms implied by law and which cannot be excluded, Tetratherix accepts no responsibility for any loss, damage, cost or expense (whether direct, or indirect, consequential, exceptional or special
damages including but not limited to loss of revenue, profits, time, goodwill, data, anticipated savings, opportunity, business reputation, future reputation, production or profit, any delay costs, economic loss or damage) incurred by you as a result of any error, omission or
misrepresentation in this presentation.
UNAUDITED INFORMATION
All forward-looking figures and proforma statements in this presentation are unaudited. Certain figures may be subject to rounding differences. All market share information in this presentation is based on management estimates having regard to internally available
information unless otherwise stated.
PRESENTATION OF INFORMATION
All currency amounts in this presentation are in Australian dollars unless otherwise stated.
I
#anchoredbyscience
Will Knox
Dr Ali Fathi
CEO
FOUNDER & CTO
Will comes from a long history of medical and biological
technology development. Prior to Tetratherix, Will has worked for
small and large businesses in Australia and offshore such as
Cochlear, Medtronic and LifeHealthcare. Will has also established
his own company in regenerative medicine that was acquired in
2017 by Australian private equity. Combining both the clinical and
commercial worlds, Will brings a unique and well respected
combination of skillsets to our business.
Ali is a world-renowned researcher and inventor of Tetramatrix
and has continued the development of the technology using
his technical and entrepreneurial vision. Ali is a globally
respected chemical engineer and is one of Australia’s most
published young researchers. Using his unique approach to
engineering science-based solutions for the real world, Ali has
created a technology that has been deliberately considered
from start to finish.
Cherie Beach
Terence Abrams
CFO
FOUNDER & COO
Cherie is the epitome of a strategic CFO and brings many years
of experience within healthcare and medical technology. Cherie
was most recently a senior finance leader at Cochlear and
Johnson&Johnson, and has a long history of strategic financial
stewardship in our industry. Cherie has an unparalleled
combination of leading global financial process with fast-growing
innovative thinking - a combination that allows us to grow rapidly
while ensuring commercial stability & reliability.
Terence (Tez) is an extremely experienced chemical engineer
who has over a decade of experience in bespoke compounding,
polymer production & infrastructure design for complex
biomaterials. Tez is the engine that drives the unique
differentiation behind our advanced manufacturing. Adopting
critical thinking and first principles, Tez is a pragmatic problem
solver who combines chemistry, quality systems and commercial
objectives - a skillset that is standalone in our industry.
PRESENTING
PRESENTING
Introduction
The executive leadership team are supported by a deep bench of scientific & commercial
advisors who are highly regarded leaders in their respective fields
1
#anchoredbyscience
Introduction
Tetramatrix™ platform technology is the world’s first biostealth fluid matrix
A fully synthetic biomaterial used to optimise precision medicine. Compatible with minimally invasive
administration techniques, with no foreign body reaction induced.
Intelligent
Tetramatrix
The material is an injectable fluid to avoid causing damage to the body during its application.
Upon injection, triggered by physiological temperature, a 3D matrix is formed that physically
integrates and adheres to the target tissue.
Modular
A biomaterial platform built with unique polymer programming akin to “medical Lego ” to
form implantable products to solve a wide range of clinical problems.
Biomimetic
The matrix has similar water content and mechanical properties to natural tissue, and therefore
is impervious to the body, bridging healthy and injured tissues, helping heal injuries or
physically manipulating the body during surgical interventions.
Safe
Due to the unique polymer programming of the material, once the matrix serves its purpose,
the material gradually and safely bioresorbs in the body with no impact locally or
systemically.
2
Supported by complete IP coverage
Patent stack with 36 granted patents from 9 families of patent,
extending to 2040 & beyond and fully owned by Tetratherix
#anchoredbyscience
Introduction
Why does the world need Tetratherix?
The evolving dynamics of the global healthcare system is demanding innovative and cost-effective biomaterials
Trends in healthcare delivery
3
How does Tetramatrix address the problem?
Rising patient expectations
Minimally invasive delivery
Patients are demanding increasingly higher quality of care, with a
particular focus on reducing recovery times and lowering risk of
complications (e.g. infection, blood loss, pain) - which is also a driver
of increasing healthcare costs for patients and payers.
Safe, biocompatible and bioresorbable
Water-based solution injected through fine gauge needle
No foreign body reaction upon application
Need for cost-effective, decentralised care
Low cost, scalable production
Increasing global healthcare spending and demand for healthcare
services is necessitating investment in cost-effective tools and
treatments, including those that can be delivered outside a traditional
hospital setting, to minimise burden on the healthcare system
Seamlessly integrated into existing workflows
Non-labour intensive, low cost and readily available materials
Delivered via needle with no additional equipment required
#anchoredbyscience
History
Company History
First patent family
and safety results
completed
Tetramatrix
Invented
2015
Series A financing
completed and
second Skeletal
Reconstruction trial
commences
First Skeletal
Reconstruction
trial completed
2017
2019
Dental commercial
partnership commences
and new polymer
configuration Invented
(used in Spacing
program)
2021
Dermal clinical trial
commenced
Spacing program
commenced with
KOLs in AU & US
2025
2023
>
2011
2016
Tetratherix
founded in Sydney
Australia
4
2018
Established
production facility
in Alexandria and
ISO:13485
certification
2020
Dermal repair
project
commenced
2022
Corporate
structure
established with
CEO hire and
commercial scale
production
established
2024
FDA engagement &
Orthopaedic
commercial
partnership
commences
Henry Schein
Partnership Master
Agreement executed
and BioOptix project
commenced
#anchoredbyscience
Franchises
Derived products from the Tetramatrix platform technology span 3 large
franchises and significant near-term commercial opportunities
Bone Regeneration
Flowable bone graft
extender for orthopaedic
applications
Bone graft extender for
dental surgeries
Tissue Spacing
Spacer during
cataract surgeries
Prostate Spacer for
radiation therapy
Tissue Healing
Intraoperative solution to reduce scar
formation after surgeries
Same core
technology, same
material and
interchangeable
dataset
5
95%
#anchoredbyscience
Commercial model
TM
Different clinical needs. Different market segments. Single Tetramatrix
platform technology.
Think of us like a SaaS business...
Bone
Regeneration
Tissue Spacing
The Tetramatrix biomaterial is our core ‘platform’ technology. We have
completed the foundational safety, efficacy and manufacturing work which is
transferable across different clinical applications of the platform.
We license the IP in a specific field to a leader in the segment. These partners
complete the “final 20%” to turn the application into a clinical product. We then
manufacture the product and supply at attractive unit economics to our industry
leading partners who distribute it though their sales channels.
+ multiple other blue
sky opportunities
Tissue
Healing
Same core technology,
same material and
interchangeable dataset
6
We enjoy periodic milestone payments as well as a steady flow of income from
product supply - a dual revenue source brings the best of both worlds.
Licensing &
Milestone
Payments
Supply of
product at
scale
#anchoredbyscience
Commercial model
A capital light model with compounding revenue
While we build our own production and R&D infrastructure, we avoid committing
capital on establishing multiple sales & distribution networks by utilising the
capabilities of our partners’ established teams.
Tissue Healing
Similar to a ‘build-to-buy’ model, we partner differently to, and at earlier stages than,
traditional medtech companies. Therefore, our return profile is different and not built
on expectations of an eventual acquisition.
Rod Drury
Xero Founder & Tetratherix Investor
7
Bone Regeneration
Design
Proof of Concept
Clinical
Validation
Regulatory
Approval
Go-to-Market
Cost
"Tetratherix is SaaS software platform thinking
applied to the vast opportunity for smart medicines.
I’m excited about the many applications that can be
delivered over time and the impact they will have to
millions of people.”
Tissue Spacing
Income
Importantly, we operate in unison with our partners. Our high margin revenue
compounds over time by adding new partnerships and launching new products.
Pipeline
Plateaued Cost
In TTX Model
Avoided Sales &
Marketing Cost by
using partners’ inmarket infrastructure
#anchoredbyscience
Unit Economics
Not simply a science experiment. TetramatrixTM provides real world economics.
Bone
Regeneration
Tissue Spacing
Tissue Healing
TAM
US$3.4bn
US$1.3bn
US$2.1bn
Payer
Patient outof-pocket
Reimbursed
(US)
Patient outof-pocket
Expected GM1 for
Partner
70-80%
~80-90%
~70-80%
Expected GM for
TTX
60-70%
~75-85%
~60-70%
We verify the final end
user pricing and the gross
margin targets for our
strategic partners before
progressing
1. Weighted Blended Gross Margin
8
#anchoredbyscience
Manufacturing
Advance manufacturing and operations
We have established advanced manufacturing in Sydney. To meet growing demand, a new facility is
planned to be commissioned in 2026, with a modular design to allow us to quickly scale as needed.
Our manufacturing process is:
Manufacturing POD
Highly Scalable with supply chain security
Our manufacturing process is design in a ‘POD’ framework whereby every POD can operate independently
The POD has a foot print of 200 sqm, and can be replicated multiple times without our facility floorspace
Allows multiple X increases in the production capacity in a fast and controlled manner
De-risked
We have previously increased our production yield per batch from laboratory scale (10 g per batch) to a commercial scale
(1.2kg) through multiple cycles of process optimisation and scale up
The production process is not labour-intensive and requires only off-the-shelf equipment
All raw materials are catalogue products and easily accessible from multiple suppliers, de-risking any supply chain risk
A new, larger site in Alexandria, Sydney has been identified with negotiations ongoing for a long-term lease
Externally Validated
Production blueprint validated for further upscale with an external European CMO
Our process has been governed by an EN ISO13485 certified quality management system since 2017 successfully completing
three re-certification audits
9
#anchoredbyscience
Tegenix
Tegenix | Bone Regeneration - Dental
A universal enabling solution to simplify complex oral &
dental procedures
Partners
An innovative carrier designed to be mixed with a broad array of bone graft materials (BGMs)
for dental and oral applications.
Key features
Gentle press-fit into the site and
adherence without primary closure
1
Mouldable and
shapable putty
Flowable
Carrier
Modular and Flexible
In situ
Mixing
Bone Graft
Simplifying Complex Procedures
10
2
Press-fit
Easy to handle and
easy to manipulate
Amenable to different graft
particles and easy to mix
A carrier system for any and every type of graft to
form mouldable and shapable composites for
easy and gentle delivery, which preserves the
integrity of the host tissue for faster healing.
Adhesive putty that
supports natural healing
Adhesive plug that negates the need for primary
closure and/or membranes which reduces the
cost, and simplifies surgical procedures,
including guided bone regeneration.
Supports Natural Healing
3
The matrix maintains the graft in 3D geometry to allow
cellular ingrowth and integration within the composite.
The biocompatible nature of the hydrogel works
synergistically with any graft, supporting natural healing.
Tegenix | Market Seeding in 2026 with a Market Leader in Dentistry
Validation Data
Pilot Clinical Trials (2X)
FDA Pathway Defined
FDA Clearance
H1 CY2026
Master Partnership Agreement
Manufacturing Ready
Market Seeding
H2 CY2026
Canine Study
Initiation
(12 weeks)
>
CY:
11
>
510k Clearance
Master
Partnership
Agreement
2025
>
Dry socket clinical trial n = >100
(9 months FPFH-LPLH)
Guided bone regeneration clinical trial
(12 months follow up)
> FDA submission
Market Access
Commercial
>
Canine Study
Implantation
(12 weeks)
Supply and
Lincencing
Agreement
>
2026
>
Indication expansion
(Dry socket)
12 month US KOL
Seeding Commences
>
510k Clearance
>
2027
>
CE Mark obtained
for EU markets
Phase 2 of US Launch with
dry socket AND grafting
2028
#anchoredbyscience
Tutelix
| Tissue Spacing - Oncology
Partners
Safe & easy to use solution for more effective & simpler
spacing in radiation oncology
TutelixTM is intended for use as a spacer to reduce side effects to surrounding tissue during
radiation therapy to treat prostate cancer. It is easily injected and is gradually resorbed by the
body and excreted over time (12 weeks) without harm to any internal organs
Key features
Procedure Optionality
1
A water-based solution makes the product amenable to
single injection after hydrodissection OR as multiple gradual
injections, two commonly used techniques.
Simple to adjust (+/- volume)
2
Injection to the space
between prostate/
rectum
12
Space generation to reduce
side effects to rectum during
radiation
Activated organically by body temperature, the solution
transitions into a hydrogel. The hydrogel is smooth, flowable
and can be immediately reversed with cold-saline. The
hydrogel breaks down to non-toxic components and
bioresorbs within 3 to 6 months completely.
Visible to physicians under both CT-scan
and ultrasound
3
In contrast to incumbent products, the product is visible
under Computed Tomography without enhancement which
allows for a safer, simpler, more accurate and cost-effective
outcome when delivering radiotherapy.
| AU/US Clinical Trial in 2026
Pivotal Trial (US)
Pilot Trial (AU)
HREC Approval
Large Animal Studies
License Agreement + JV
AU/ US Clinical Trial
US KOL
Engagement
HREC and
Site
Approval
Commercial
CY:
13
>
>
Cohort 1
Implant
Placement
US KOL Program with early
engagement
>
In CY2027
FDA Clearance
In CY2028
In 2026
FDA-IND Clinical Trial (Pivotal, n=300, multicentre)
FPFV-LPLV= 18 months
>
Results Released for
Pivotal Trial
n = 300 patients
Results Released for
Pilot Trial n = 30 patients
FPFV=LPLV= 18 months
Primary Endpoint
Results for Cohort 1
>
2025
>
Quality and Supply Agreement
Series A Financing
of AU$10m
2026
>
Commercialisation Window with
Strategic Partner
2027
>
510k
OVB
Clearance
2028
#anchoredbyscience
Optelex
Optelex | Tissue Spacing - Ophthalmology
TM
Partners
Novel Synthetic reversible OVD for safe & simple application
Optelex is a fully synthetic solution that maintains the volume and shape of the eye during
surgery that can be removed via a simple saline wash. The product reduces the reliance of
partners on animal derived materials. Most importantly, by reversing the gelation of the
product by cold saline dissolution, the risks associated with inflammation from product
residues - a common risk for all current products- is fully mitigated.
Key features
1 Synthetic - Not animal-derived
The product is fully synthetic and there is no animal derived
component used in the product, which provides supply chain
security to the partner
2 Low cost and scaled manufacturing
Ready to use cohesive
and dispersive OVD.
Transparent structure that
remains within the eye
during surgeries.
Reverse gelation by using
cold saline to wash
product residues
Low cost of goods, scalable production and controlled
sterility and endotoxins provide commercially attractive unit
economics
3 Easy to remove & reduces known side effects
The product’s instant dissolution by lowering the temperature
of the site via cold saline, allows easy and fast removal of the
product after the completion of the surgery.
14
Optelex | First I US Clinical Trial in 2027
TM
Master Partnership Agreement
Supply and License Agreement
H2 CY2025
Invention and patent submission
Clinical Trial
CY2027
Product
Development
Formulation and
patent
submission
>
Product Fomulation and
Safety studies in animals
Commercial
Master
Partnership
Agreement
>
Supply and
License
Agreement
CY:
15
Results Released for Pivotal
Trial n = 300 patients
FDA-IND Clinical Trial
(Pivotal, n=300, multicentre)
Pivotal Trial (US)
2025
>
US KOL Program with
early engagement
2026
>
Mid CY2025
FDA Correspondence
Commercialisation Window with
Strategic Partner
2027
FDA submission
2028/2029
2028
#anchoredbyscience
TetraDerm
TetraDerm | Tissue Healing
Partners
The world’s first intraoperative scar prevention solution
TetraDerm is the only flowable matrix that can be used intraoperatively to provide an internal
cushioning effect to physically decrease mechanical tension and dead space, therefore
reducing scar formation after any surgery, such as surgical reconstruction, arthroplasty and
caesarean procedures
Surgical
Wound
>
Sub-dermis
suturing
>
Product
administration
& gelation
>
Product
cushioning effect
Key features
1
Easy to apply and able to be
used intraoperatively
2
Superior efficacy in tissue remodelling
and wound closure
A flowable dermal matrix that forms a uniform hydrogel within
dermal layers without the need for any external stimuli, such as
light or chemical reaction- gelation is triggered by physiological
temperature.
The mimetic of the hydrogel allows biological integration of the
hydrogel within the host tissue and provides a physical scaffold for
cellular regeneration and skin remodelling.
3
Decreases myofibroblast activity and scar
formation
Mechanical tension is the driving force known to increase
myofibroblast activity and consequently scar formation. The matrix
provides an internal cushioning effect to reduce mechanical
tension and dead space, thus preventing scar formation.
16
TetraDerm | Ongoing Clinical Data Readout
Technical Validation
FDA Correspondence
Clinical Trial
FDA Clearance
Pilot Clinical Trial
Clinical trial Cohort 1 n=8
Cohort 2 Initiation n=18
Market Access
17
Manufacturing Ready
1H CY2029
Cohort 3 Initiation n=27
Interim Report
Primary End Point
FDA Pre Submission
Commercial
CY:
Customer Need Identified
Clinical Study
Report (CSR)
Large Animal Model
De Novo 510k
Submission
Licencing Window
2025
2026
2027
2028
#anchoredbyscience
Near Term Milestones
Relentless execution with Regular newsflow in first 12 months post-listing
Bone
Regeneration
DENTAL
FDA Studies on
Track
Henry Schein Supply and
Licensing agreement
execution
ORTHOPAEDIC
FDA Studies on
Track
Master Partnership
Agreement
execution
ONCOLOGY
FDA Presubmission/
Regulatory
Pathway Defined
OPHTHALMIC
BioOptix
Licensing
Agreement
Strategic global
partnership
SURGICAL
SITE MGMT
Cohort 2
Commenced
Year 1 Follow up
for Cohort 1 results
published
Data Read-out from the
FDA study
FDA Submission
Supply and Licensing
agreement execution
FDA Submission
FDA
Clearance
FDA
Clearance
Tissue Spacing
Tissue Healing
Roadshow
18
Tutelix First In
Human Cohort 1
(n=3)
FY2026
Quality
Agreement
execution
US/AU
Capital Raise
US/ AU
Capital Raise
Tutelix Primary End
Point for Cohort 2
(n=15 to 30)
Preclinical Data
Read-out
Primary
End-point
Cohort 2
FDA Presubmission/
Regulatory Pathway
US Clinical Trial
Initiation
FDA Pre-submission/
Regulatory Pathway
TetraDerm Cohort
3 Initiation
(major surgeries)
FY2027
#anchoredbyscience
Strategic Licence Agreement signed with BioOptix Inc.
Tetratherix and the New York-based ophthalmic company will develop and commercialise a novel ophthalmic viscoelastic device (OVD), built upon Tetratherix'
polymer platform.
Global OVD market is estimated to have a total addressable value of USD ~$700 million p.a., with minimal
innovation in recent decades,
Tetratherix invented two new polymer formulations (PH2O and PH2NO) to address the shortcomings in OVD
applications. A new Australian Provisional Patent has been submitted. The forming products are flowable and forms
transparent gel as opposed to white/opaque structure.
Partnership model enables rapid commercial entry into targeted markets & capital-light model for Tetratherix, with
BioOptix responsible for funding clinical & regulatory activities through a 5+5+5 years agreement.
Tetratherix will provide its platform technology, products, services, technical support, and testing in return for a
licence fee during the development phase
Tetratherix will continue to manufacture the products at its Australian facilities during the commercialisation phase
with minimum purchase volumes agreed, operating under its ISO13485 certified quality management system
BioOptix will manage capital raising for the venture and engage with leading VC firms in the US as well as strategic
partners
19
#anchoredbyscience
Copyright
Tetratherix Pty Ltd. 2025 “Tetratherix”
Share your feedback
Discover